Fulgent Genetics Inc   (FLGT)
Other Ticker:  
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare
Price: $24.2600 $0.20 0.831%
Day's High: $24.36 Week Perf: -2.26 %
Day's Low: $ 23.88 30 Day Perf: -6.55 %
Volume (M): 261 52 Wk High: $ 44.09
Volume (M$): $ 6,322 52 Wk Avg: $30.98
Open: $23.93 52 Wk Low: $23.09

 Market Capitalization (Millions $) 728
 Shares Outstanding (Millions) 30
 Employees 284
 Revenues (TTM) (Millions $) 285
 Net Income (TTM) (Millions $) -65
 Cash Flow (TTM) (Millions $) -85
 Capital Exp. (TTM) (Millions $) 24

Fulgent Genetics Inc
Fulgent Genetics Inc. is a technology-based genetic testing company that offers a range of genetic testing solutions to medical professionals, researchers, and patients. It focuses on providing genetic testing services for various cancer-related and genetic diseases.

Founded in 2011 and based in Temple City, California, Fulgent Genetics Inc. offers a wide range of next-generation sequencing (NGS) and microarray products and services. These include genetic testing panels, whole-exome sequencing, carrier screening, prenatal testing, and pharmacogenetics testing.

The company's mission is to improve patient outcomes by providing high-quality, affordable genetic testing solutions that enable clinicians and researchers to make better-informed decisions for their patients. Its approach is characterized by a focus on quality, speed, and affordability of its testing services.

Fulgent Genetics Inc.'s technology platform is based on its proprietary CAP-accredited and CLIA-certified technology which has enabled the company to rapidly scale its genetic testing capabilities. It has also enabled the company to deliver accurate and reliable results at lower prices than many of its competitors.

The company's comprehensive genetic testing portfolio includes its flagship FulgentOnee Suite of Tests, which includes more than 18,000 genes in its clinical diagnostic exome sequencing tests. This suite of tests is designed to provide physicians with a variety of options to choose from, depending on their patients' specific needs.

Fulgent Genetics Inc. has built a vast network of more than 10,000 US-based clinicians and researchers who rely on its genetic testing services. The company also has partnerships with several major healthcare providers and pharmaceutical companies.

In recent years, Fulgent Genetics Inc. has seen significant growth in its business, driven by an increase in demand for genetic testing services among healthcare professionals and consumers. In 2020, the company reported over $339 million in revenue, an increase of 542% from the previous year.

Overall, Fulgent Genetics Inc. is one of the leading genetic testing companies in the US, offering a range of high-quality and affordable genetic testing services to its clients. With its commitment to innovation and technology, the company is well-positioned to continue growing in the years to come.

   Company Address: 4399 Santa Anita Avenue El Monte 91731 CA
   Company Phone Number: 350-0537   Stock Exchange / Ticker: NASDAQ FLGT
   FLGT is expected to report next financial results on February 28, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Fulgent Genetics Inc

Fulgent Genetics Inc's Financial Woes Deepen with Losses Soaring to -$0.44 per Share in Q3 2023

/>Fulgent Genetics Inc., a technology-based company operating in the clinical diagnostic and therapeutic development sectors, recently reported its financial results for the third quarter ending September 30, 2023. Although the Medical Laboratories industry experienced growth during this period, Fulgent Genetics faced weaknesses in orders, leading to increasing losses and a decline in revenue. This article aims to analyze the impact of these financial results on the company's future prospects.
Weak Orders Contribute to Increased Losses and Decreased Revenue:
During the third quarter of 2023, Fulgent Genetics Inc.'s net deficit per share rose from $0.06 to $-0.44, indicating a significant increase in losses. Furthermore, the company's revenue declined by 20.644% to $83.84 million, down from $105.66 million in the previous year. The weak orders are the primary factor behind these unfavorable financial results.

Fulgent Genetics Inc

Fulgent Genetics Inc Reports Staggering Revenue Decline of 46.089% for Second Quarter of 2023, Despite Sequential Advance and EPS Improvement

Fulgent Genetics Inc, a leading provider of genetic testing services, recently reported its financial results for the April to June 30, 2023 interval. While the company experienced a decrease in returns per share compared to the previous year, there were some positive indicators in terms of improved earnings per share and sequential revenue growth.
In terms of earnings per share, Fulgent Genetics Inc saw a decline from $0.37 per share in the previous year to a loss of $-0.38 per share in the current reporting period. However, it is worth noting that the company's EPS improved from a loss of $-0.52 per share in the previous reporting period. This indicates that the company has made progress in reducing its losses.

Fulgent Genetics Inc

Fulgent Genetics Inc Faces Mounting Challenges, Suffers Major Setback with $27 Million Net Loss in Q1 2023

Fulgent Genetics Inc Reports Cumulative Net Loss of $-27 Million in First Quarter 2023
Fulgent Genetics Inc, a leading player in the Medical Laboratories industry, has recently reported a negative return on equity (ROE) of -2.14%, with a cumulative net loss of $-27 million during the 12 months ending in the first quarter 2023. This news comes as a setback for investors who were looking for a more positive performance from the company during this period.
The company is currently ranked at 1208 in terms of total ranking, a significant deterioration from the fourth quarter of 2022 when the ranking stood at 712. Despite efforts to improve the performance, 8 other companies in the Medical Laboratories industry have been able to achieve a higher return on equity.


Fulgent Genetics Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com